

MDxHealth's New Share Capital Amount and New Number of Shares

IRVINE, CA, and HERSTAL, BELGIUM – 19.30 p.m. CEST, May 5, 2017 – MDxHealth SA (the “Company”) (Euronext Brussels: MDXH) announced today, in conformity with Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers shares of which are admitted to trading on a regulated market, that on May 5, 2017, 103,813 new ordinary shares were issued by MDxHealth resulting from the exercise of 103,813 warrants.

As a result of the aforementioned exercise of warrants, the share capital of MDxHealth increased from EUR 39,761,328.75 to EUR 39,844,140.38, and the number of outstanding shares increased from 49,845,595 to 49,949,408. All outstanding shares have voting rights.

In addition to the outstanding shares, the total number of outstanding warrants on the date of this press release amounts to 2,041,250 warrants which (if exercised) would entitle their holders to 2,041,250 shares with voting rights.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information visit www.mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:

Shalon Roth, EVP Corporate Communications
MDxHealth
UK: +44 (0)7393 906278
@ShalonRoth
info@mdxhealth.com

Important information

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.